ytterbium has been researched along with Astrocytoma, Grade IV in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hong, S; Im, K; Kang, JH; Kang, M; Lee, J; Lee, TS; Lim, SM; Park, S; Ryu, J; Song, R | 1 |
| Freitag, P; Gratzl, O; Hausmann, O; Jermann, E; Mäcke, HR; Merlo, A; Müller-Brand, J; Otte, A; Reubi, JC; Steiner, P; Wasner, M | 1 |
1 trial(s) available for ytterbium and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas.
Topics: Adult; Astrocytoma; Binding, Competitive; Brain Edema; Brain Neoplasms; Diffusion; Disease Progression; Female; Glioblastoma; Glioma; Humans; Injections, Intralesional; Male; Middle Aged; Neoplasm Proteins; Octreotide; Oligodendroglioma; Pilot Projects; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Receptors, Somatostatin; Stereotaxic Techniques; Tissue Distribution; Ytterbium | 1999 |
1 other study(ies) available for ytterbium and Astrocytoma, Grade IV
| Article | Year |
|---|---|
RGD peptide-conjugated multimodal NaGdF4:Yb3+/Er3+ nanophosphors for upconversion luminescence, MR, and PET imaging of tumor angiogenesis.
Topics: Animals; Cell Line, Tumor; Dimerization; Erbium; Feasibility Studies; Fluorides; Gadolinium; Glioblastoma; Humans; Integrin alphaVbeta3; Iodine Radioisotopes; Luminescent Agents; Luminescent Measurements; Magnetic Resonance Imaging; Mice; Molecular Imaging; Nanostructures; Neovascularization, Pathologic; Oligopeptides; Polyethylene Glycols; Positron-Emission Tomography; Ytterbium | 2013 |